Scarica l'app Stockscreener
1.54
3.36%
0.05
Dopo l'orario di chiusura:
1.55
0.01
+0.65%
Precedente Chiudi:
$1.49
Aprire:
$1.54
Volume 24 ore:
60,569
Relative Volume:
1.21
Capitalizzazione di mercato:
$8.97M
Reddito:
-
Utile/perdita netta:
$-14.29M
Rapporto P/E:
-0.386
EPS:
-3.99
Flusso di cassa netto:
$-12.27M
1 W Prestazione:
+4.27%
1M Prestazione:
+5.84%
6M Prestazione:
+0.19%
1 anno Prestazione:
-56.00%
Intervallo 1D:
$1.50
$1.5696
Intervallo di 1 settimana:
$1.395
$1.57
Portata 52W:
$1.37
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Nome
Aprea Therapeutics Inc
Settore
Industria
Telefono
215-948-4119
Indirizzo
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Confronta APRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.54 | 8.80M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-06-22 | Iniziato | H.C. Wainwright | Neutral |
| 2020-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2019-10-28 | Iniziato | JP Morgan | Neutral |
| 2019-10-28 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
Aprea sets 1,100 mg dose for ATR inhibitor, shifts focus to combinations - Investing.com Nigeria
Visualizing Aprea Therapeutics Inc. stock with heatmaps2025 Risk Factors & Consistent Profit Trading Strategies - newser.com
Risk vs reward if holding onto Aprea Therapeutics Inc.Earnings Recap Summary & Community Supported Trade Ideas - newser.com
Is Aprea Therapeutics Inc. stock poised for growthEarnings Beat & Growth Focused Stock Reports - newser.com
Aprea sets 1,100 mg dose for ATR inhibitor, shifts focus to combinations By Investing.com - Investing.com South Africa
Aprea Therapeutics Shifts Focus to Combination Therapies - TipRanks
Aprea Therapeutics Establishes Recommended Phase 2 Dose for ATRN-119 - TradingView
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies - The Manila Times
1,100 mg RP2D: Aprea Therapeutics shifts ATRN-119 to combination focus, pauses monotherapy enrollment - Stock Titan
Aprea Therapeutics Announces Presentations at - GlobeNewswire
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics - Stock Titan
Sentiment analysis tools applied to Aprea Therapeutics Inc.Market Activity Summary & Fast Exit/Entry Strategy Plans - newser.com
Developing predictive dashboards with Aprea Therapeutics Inc. dataInsider Selling & AI Powered Market Trend Analysis - newser.com
How to recover losses in Aprea Therapeutics Inc. stock2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
Using economic indicators to assess Aprea Therapeutics Inc. potential2025 Breakouts & Breakdowns & Safe Entry Zone Tips - newser.com
Should you wait for a breakout in Aprea Therapeutics Inc.July 2025 Selloffs & Smart Investment Allocation Insights - newser.com
Aprea Therapeutics (NASDAQ:APRE) Trading Down 3% – Here’s What Happened - Defense World
Historical volatility pattern of Aprea Therapeutics Inc. visualizedPortfolio Growth Summary & Daily Growth Stock Tips - newser.com
Can Aprea Therapeutics Inc. rally from current levelsWeekly Trend Report & Long-Term Growth Stock Strategies - newser.com
How sentiment analysis helps forecast Aprea Therapeutics Inc.Market Rally & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-03 04:24:53 - newser.com
How to integrate Aprea Therapeutics Inc. into portfolio analysis toolsJuly 2025 Selloffs & Precise Swing Trade Alerts - newser.com
Reversal indicators forming on Aprea Therapeutics Inc. stockJobs Report & Verified Chart Pattern Signals - newser.com
What analysts say about Aprea Therapeutics Inc stockPrice Support Zones & Low Cost Trading Plans - earlytimes.in
Published on: 2025-09-30 01:07:35 - newser.com
Published on: 2025-09-29 04:10:00 - newser.com
What drives Aprea Therapeutics Inc stock priceTrade Execution Strategies & Big Returns Small Capital - earlytimes.in
Is Aprea Therapeutics Inc a good long term investmentMACD Trading Signals & Rapid Capital Trading Tips - Early Times
Published on: 2025-09-27 17:04:35 - newser.com
Live market analysis of Aprea Therapeutics Inc.2025 Sector Review & Stock Portfolio Risk Control - newser.com
Using portfolio simulators with Aprea Therapeutics Inc. includedJuly 2025 Trends & Weekly Market Pulse Alerts - newser.com
Aprea Therapeutics Inc Azioni (APRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aprea Therapeutics Inc Azioni (APRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Duey Marc | Director |
Oct 18 '24 |
Sale |
4.58 |
6,462 |
29,583 |
233,651 |
| Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):